Jeffrey P. Tillinghast

Internal Medicine
969 N Mason Rd Ste 240
Saint Louis, MO 63141

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.

Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.

Journal: The Journal of allergy and clinical immunology
Published: May 30, 2023
Showing 1-1 of 1

Last Updated: 09/26/2026